PharmaFocus Today – Page 100 – media

Bivalent HPV is hit hard! Wantai Biopharmaceuticals’ vaccine volume and price both fell, betting on nine-valent may become the last trump card

In the past two years, Wantai Bio ‘s performance data has fallen off a cliff, hitting a new low since its listing. The once “star enterprise” of vaccines is experiencing the most severe performance winter in history. The core driver of the sharp drop in performance is the “big decline” in the vaccine business. Wantai Biological , which once seized the market with the first domestically produced bivalent HPV vaccine “Xinkening” , is now facing the impact of the entry of competitors such as Watson Biological and the expansion of the age range of Merck’s nine-valent vaccine squeezing the market. Faced with difficulties, Wantai Biopharmaceuticals is pinning its hopes on the nine-valent HPV vaccine, which has not yet been approved for marketing. However, this vaccine, which is planned to be a “blockbuster product”, will have to face dual competition from Merck’s “Gardasil 9” (which already covers men) and Watson Biopharmaceuticals ...
- Source: drugdu
- 222
- May 30, 2025
The United States will no longer recommend routine COVID-19 vaccinations for healthy children and pregnant women

On May 27th local time, Robert F. Kennedy Jr., Secretary of the U.S. Department of Health and Human Services (HHS), announced that routine COVID-19 vaccination will no longer be recommended for healthy children and pregnant women. The U.S. Centers for Disease Control and Prevention (CDC) previously recommended that all infants 6 months and older should be vaccinated against the new coronavirus. Just a week ago, the U.S. Food and Drug Administration (FDA) announced that the agency plans to limit the use of the new crown vaccine to the elderly, children and adults with underlying medical conditions. The FDA last week released new regulatory guidance for future COVID-19 vaccine boosters, setting stricter approval standards for vaccination of healthy Americans. The FDA said that vaccines developed against new variants need to be re-approved before they can be marketed. Previously, the FDA usually approved the new crown vaccine for vaccination in all Americans ...
- Source: drugdu
- 173
- May 30, 2025
Kangtai Biological’s trivalent influenza vaccine clinical trial application accepted

On May 28, Kangtai Biological (300601) issued an announcement that it had received an acceptance notice issued by the National Medical Products Administration today, agreeing to accept the clinical trial application for the trivalent influenza virus split vaccine (MDCK cells) jointly developed by the company and Lanzhou Bailing Biotechnology Co., Ltd. The vaccine is suitable for people aged 3 years and above and is intended to stimulate the body to produce immunity against influenza viruses to prevent influenza caused by related types of influenza viruses. In the first quarter of 2025, Kangtai Biological achieved revenue of 645 million yuan and net profit attributable to shareholders of the parent company of 22.43 million yuan. https://finance.eastmoney.com/a/202505283416827087.html
- Source: drugdu
- 188
- May 30, 2025
Fosun Pharma’s self-developed MEK inhibitor has been approved for marketing in China. This drug can treat related rare blood tumors

On May 29, Fosun Pharma announced that its independently developed Class 1 new drug Ruvometinib Tablets (trade name: Fumainin®) was officially approved for marketing by the National Medical Products Administration (NMPA). As a highly selective MEK1/2 inhibitor, Fumainin was approved for two indications for the treatment of adult patients with Langerhans cell histiocytosis (LCH) and histiocytic tumors, and children and adolescents aged 2 years and above with neurofibromatosis type I (NF1) with symptomatic, inoperable plexiform neurofibromas (PN). Fosun Pharma’s Ruvometinib has been approved for marketing, filling the gap in the treatment of rare tumors such as adult LCH. It works by blocking key signaling pathways, with impressive clinical efficacy and safety, and subsequent research and development of multiple indications is worth looking forward to. https://www.nbd.com.cn/articles/2025-05-29/3893732.html
- Source: drugdu
- 269
- May 30, 2025
The company’s products have obtained medical device registration certificates

Jianfan Bio announced on the evening of May 28 that Jianfan Biotechnology Group Co., Ltd. recently received the ” Medical DeviceThe company’s new product, disposable waste liquid bag, has obtained the second-class medical device registration certificate. This new product is a waste liquid collection device during blood purification treatment. From January to December 2024, Jianfan Bio ‘s operating income structure is as follows: medical device manufacturing accounted for 99.71%, and others accounted for 0.29%. https://finance.eastmoney.com/a/202505283416906248.html
- Source: drugdu
- 195
- May 29, 2025
Kangtai Biological’s application for clinical trial of trivalent influenza vaccine has been accepted

On May 28, Kangtai Biological issued an announcement that it received an acceptance notice issued by the National Medical Products Administration today, agreeing to accept the trivalent influenza vaccine jointly developed by the company and Lanzhou Bailing Biotechnology Co., Ltd.Clinical trial application for viral split vaccine (MDCK cells). The vaccine is suitable for people aged 3 years and above and is intended to stimulate the body to produce immunity against influenza viruses to prevent influenza caused by related types of influenza viruses. In the first quarter of 2025, Kangtai Biological achieved revenue of 645 million yuan and net profit attributable to shareholders of the parent company of 22.43 million yuan. 网址：https://finance.eastmoney.com/a/202505283416827087.html
- Source: drugdu
- 206
- May 29, 2025
1.6 billion! A well-known Vietnamese pharmaceutical company was acquired

Recently, Livzon Pharmaceutical announced that its wholly-owned overseas subsidiary LIAN SGP signed an agreement with the sellers (SK, Sunrise and KBA) to acquire 64.81% of the shares of Imexpharm Corporation (IMP), a Vietnamese listed company held by the sellers, at a purchase price of 573.08 billion Vietnamese dong (approximately RMB 1.587 billion). Public information shows that IMP is a leading pharmaceutical company in Vietnam, founded in 1977 and listed on the Ho Chi Minh City Stock Exchange in 2006. According to the list of the top ten well-known pharmaceutical companies in 2024 published by Vietnam Report Joint Stock Company (Vietnam Report), IMP ranked third. Imexpharm is mainly engaged in the research and development, production and sales of drugs, and its products mainly include antibiotics, cardiovascular and cerebrovascular drugs, etc. At present, Imexpharm has 4 factories and 25 retail branches in various provinces and cities in Vietnam. In terms of market ...
- Source: drugdu
- 304
- May 29, 2025
PD-1+LAG3 work together to “break through”

The 2025 ASCO Annual Meeting is about to be held. At present, the regular abstracts have been released to the public, and many domestic new drugs have performed well. Among them, LBL-007 of Weilizhibo has made its debut again with breakthrough data. This is the fifth consecutive year that the drug has been selected for the ASCO meeting. LBL-007 is a fully human IgG4 monoclonal antibody targeting LAG3. Its clinical progress ranks among the top three in the world (except for the only LAG3-targeted drug on the market). It is also the first antibody of its kind to be proven to be effective against nasopharyngeal carcinoma. Clinical data show that LBL-007 combined with first-line therapy for NPC patients has an ORR of 83.3% and a median PFS of 15.8 months, which is significantly higher than the existing standard regimen. With its excellent safety and efficacy, LBL-007 is expected to become ...
- Source: drugdu
- 247
- May 29, 2025
Integrating pharmacogenomics into everyday clinical practice can transform patient care

Pharmacogenomics studies how individuals respond to drugs based on their genetic code. Using that knowledge to guide prescribing in routine care could lead to better outcomes for patients and save money for health systems. Generating pharmacogenomic data in the laboratory is relatively straightforward, but a major challenge is making that information available to frontline healthcare professionals in a clinically relevant format and timeframe. This has meant that, to date, only a limited numbers of patients have been able to benefit from such individually optimised treatments. Dr. John McDermott, NIHR Academic Clinical Lecturer at the University of Manchester, Manchester, UK, will describe to the annual congress of the European Society of Human Genetics today (Tuesday) how he and colleagues, as part of the NHS-England Network of Excellence for Pharmacogenomics & Medicines Optimisation, have pioneered an approach to integrate genomic data into electronic health records in both GP practices and hospitals. This ...
- Source: drugdu
- 164
- May 28, 2025
MRI scans reveal why young women face higher risk for eating disorders

Breakthrough MRI scans reveal hidden hypothalamic changes in young women, shedding light on the biological roots of anorexia and obesity, and paving the way for targeted treatments. A recent editorial feature published in the American Journal of Clinical Nutrition discusses the use of a novel imaging technique to investigate how certain structural features of the hypothalamus affect eating behaviors. A new approach to studying the hypothalamus Women are more likely to develop eating disorders like anorexia nervosa than men, particularly during puberty. Despite this disproportional occurrence, few studies have investigated the role of the female brain in neuroscience and psychiatry. The hypothalamus is a small, heterogeneous brain structure in the diencephalon that regulates homeostatic and hedonic functions involved in feeding behaviors. Current imaging techniques are limited in their ability to capture nuclei subsegmentation within the hypothalamus. As a result, most studies investigating the role of the hypothalamus have been conducted ...
- Source: drugdu
- 165
- May 28, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.